We are a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Our initial product candidate is STS101 (dihydroergotamine (DHE) nasal powder), which we are focused on developing as an important and differentiated therapeutic option for the acute treatment of migraine